# Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

> **NCT05971199** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 27 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Fruquintinib
- **DRUG:** Sintilimab
- **DEVICE:** Transcatheter arterial chemoembolization（TACE）

## Key facts

- **NCT ID:** NCT05971199
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-23
- **Primary completion:** 2024-12-23
- **Final completion:** 2024-12-23
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2023-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05971199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05971199, "Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05971199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*